In August 2014, MSAA posted a news item announcing that the Multiple Sclerosis Coalition (MSC) had published a paper detailing the current evidence that supports the FDA-approved disease-modifying therapies (DMTs) for the long-term treatment of multiple sclerosis (MS). This paper was written expressly for healthcare providers and the health-insurance industry.

On April 16, 2015, the United States Food and Drug Administration (FDA) approved Glatopa™ (glatiramer acetate injection) for the treatment of individuals with relapsing forms of multiple sclerosis (MS), including those who have experienced a first clinical episode and have magnetic resonance imaging (MRI) features consistent with MS.

Individuals living with multiple sclerosis (MS) often find that heat and humidity aggravate common MS symptoms. In addition to advice such as using air conditioning and sipping cool beverages throughout the day, individuals living with MS may also benefit from the use of special cooling equipment to help maintain an ideal body temperature.

For the more than 400,000 Americans living with multiple sclerosis (MS), the support of loved ones, care partners and organizations such as the Multiple Sclerosis Association of America (MSAA) is crucial to improving quality of life. To help increase awareness of this disease, MSAA is taking part in observing March as MS Awareness Month.

The member organizations of the Multiple Sclerosis Coalition (MSC) unanimously endorsed the American Academy of Neurology’s (AAN) position statement entitled Availability of Disease Modifying Therapies (DMT) for Treatment of Relapsing Forms of Multiple Sclerosis.

Health experts tout swimming as one of the best all-around, total-body workouts. It builds both strength and cardiovascular endurance, and is well-suited for all ages and abilities.